Table 2.

Preoperative laboratory characteristics and antisecretory drug requirement of gastric acid normosecretors and hypersecretors postcurative resection⁽¹⁾

Preoperative Characteristic	Number (percent)(6)
	Normosecretors	Hypersecretors
	(n=19)	Moderate (n=17)	Extreme (n=14)
Basal acid output (mEq/h)	28.9 ± 4.5	41.0 ± 6.1	57.9 ± 6.6(a, c)
Maximal acid output (mEq/h)	43.9 ± 6.2	67.2 ± 8.8(b)	87.6 ± 7.5(a)
Fasting serum gastrin (pg/ml)	1284 ± 450	1200 ± 422	1435 ± 616
Delta secretin (pg/ml)(2)	2143 ± 612	1550 ± 589	2417 ± 778
Preoperative Antisecretory treatment
Drug(3)
Histamine H2-inhibitors	9 (47%)	7 (41%)	3 (21%)
Omeprazole	10 (53%)	10 (59%)	11 (79%)
Duration (yrs)(4)
Total	4 ± 1	5 ± 1	3 ± 1
Histamine H2-inhibitors	3 ± 1	2 ± 1	2 ± 1
Omeprazole	2 ± 1	3 ± 1	2 ± 1
Dosage (mg/d)(5)
Histamine H2-inhibitors	1284 ± 454	2203 ± 318	1426 ± 122
Omeprazole	52 ± 8	66 ± 13	65 ± 18

Compared to normosecretors:

^(a)P <0.001,

^(b)P <0.03: Compared to moderate hypersecretors:

^(c)P <0.05.

⁽¹⁾Secretory groups are as defined in Table 1 legend.

⁽²⁾Increase in serum gastrin level following secretin injection [28].

⁽³⁾This is the last gastric acid antisecretory drug used prior to surgery.

⁽⁴⁾Total duration is the total time the patient was treated with any gastric acid antisecretory drug prior to curative resection.

⁽⁵⁾Dose of antisecretory drug patient was taking at the time of curative resection. All histamine H₂-inhibitors were converted to ranitidine equivalents as previously described [26,80].

⁽⁶⁾Number and percent are as defined in Table 1 legend.